Details of the Drug Combination

General Information of Drug Combination (ID: DCZ7GRB)

• Drug Combination Name: Hepzato + Altretamine
• Indication: Malignant melanoma; Status: Investigative [1]
• Component Drugs:
  Hepzato (DM2AZPP): N.A.
  Altretamine (DMKLAYG): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: UACC62
  Zero Interaction Potency (ZIP) Score: 0.89
  Bliss Independence Score: 1.77
  Loewe Additivity Score: 0.2
  LHighest Single Agent (HSA) Score: 0.14

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[2]

Indication(s) of Altretamine

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Approved	[3]

Altretamine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[4]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Astrocytoma	DCZDCNS	SNB-19	Investigative	[5]
Plasma cell myeloma	DCXJY3D	RPMI-8226	Investigative	[5]
Adenocarcinoma	DCI8LHI	A549	Investigative	[1]
Adenocarcinoma	DCPQW7D	HCC-2998	Investigative	[1]
Amelanotic melanoma	DCDJLK2	MDA-MB-435	Investigative	[1]
Cutaneous melanoma	DCM52U7	SK-MEL-5	Investigative	[1]
Large cell lung carcinoma	DCPYLAI	NCI-H460	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
• [4] Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.